Organization | Kagawa University

Kagawa University Report issue

Academic/Hospital Phase 3 Phase 4

Founded: Takamatsu Japan (1874)

Organization Overview

First Clinical Trial

2010

NCT01184599

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2016

Timeline

NOW

Now

Alternative names

Kagawa Univerisity Faculty of Medicine | Kagawa University | Kagawa University School of Medicine

Active Ingredients

Drugs in Phase 4 Trials (5)

aflibercept (zaltrap) (1 trial)

aliskiren (tekturna) (1 trial)

pegaptanib (macugen) (1 trial)

ranibizumab (lucentis) (1 trial)

verteporfin (visudyne) (1 trial)

Drugs in Phase 3 Trials (2)

caffeine (1 trial)

encenicline (2 trials)

Drugs in Other Trials (2)

d-allulose (3 trials)

enzalutamide (xtandi) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Alzheimer Disease (Phase 3)

Apnea (Phase 3)

Glomerulonephritis (Phase 4)

Glomerulonephritis, IGA (Phase 4)

Premature Birth (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 9
# of Trial APIs: 9